{"analyses":[{"ciLowerLimit":"22.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"40.6","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Rate difference","paramValue":"31.6","statisticalComment":"If any cell count was \\<5, p-value was based on Fisher's exact test","statisticalMethod":"1-sided p-value based on Chi-square test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.0","upperLimit":"50.6","value":"42.7"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"17.0","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"162"}],"units":"Participants"}],"description":"HSCT rate was defined as the percentage of participants who underwent SCT following treatment with inotuzumab ozogamicin or Investigator's choice of chemotherapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were treated with inotuzumab ozogamicin at a starting dose of 1.8 mg/m\\^2 (according to body surface area) per cycle with a divided-dose regimen using 3 weekly administrations. Participants received 0.8 mg/m\\^2/cycle on Week 1 (Day 1), followed by 0.5 mg/m\\^2 on Week 2 (Day 8) and Week 3 (Day 15) of a 21-day cycle, and administered as an intravenous infusion over 60 minutes. For participants who achieved a CR or CRi, or to allow recovery from toxicity, the length of Cycle 1 could be extended up to 28 days (ie, 1 week treatment-free interval starting on Day 21). For participants who achieved CR or CRi, the inotuzumab ozogamicin dose administered on Week 1 was reduced to 0.5 mg/m\\^2 (for a total cycle dose of 1.5 mg/m\\^2/cycle) for Cycles 2 through 6 (maximum number of cycles permitted). For Cycles 2 through 6, the cycle length was 28 days for all participants (regardless of remission status).","id":"OG000","title":"Inotuzumab Ozogamicin"},{"description":"Participants received fludarabine, cytarabine, granulocyte-colony stimulating factor (FLAG), mitoxantrone + cytarabine (MXN/Ara-C), or high-dose cytarabine (HIDAC), according to the Investigator's choice.","id":"OG001","title":"Defined Investigator's Choice of Chemotherapy"}],"paramType":"NUMBER","populationDescription":"ITT population. Although only 143 participants were treated in the Defined Investigator's Choice of Chemotherapy arm, all 162 randomized participants were included in the ITT population.","reportingStatus":"POSTED","timeFrame":"Up to 19 weeks from last dose","title":"Percentage of Participants Who Had a Hematopoietic Stem-Cell Transplant (HSCT)","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}